Christin L. Melton | Authors


Targeted Therapies End the Dry Spell in AML Drug Development

February 06, 2019

Targeted agents are routinely used to treat many cancers and have improved outcomes for patients with solid tumors and hematological malignancies alike. Recently, targeted therapies made their way into the armamentarium for acute myeloid leukemia, representing the first therapeutic advances for AML in decades.